

**David Neasham, MS, PhD**  
**Epidemiologist, i3 Drug Safety**

David Neasham received a Master of Science Degree in Epidemiology from the London School of Hygiene and Tropical Medicine, and a Ph.D. in Epidemiology & Public Health Medicine from the Faculty of Medicine, Imperial College London. Prior to joining i3 Drug Safety, Dr. Neasham was faculty lecturer in epidemiology at Imperial College and co-principal investigator and clinical manager on a £10M Health Monitoring Program to look at the health of the British Police Force. He has strong interests in cancer, cardiovascular and perinatal epidemiology and expertise in the design, management and implementation of various kinds of epidemiological research including randomized controlled trials, case control, cohort, and spatio-temporal analyses of large geographical, environmental and epidemiological datasets. Dr. Neasham has published in international journals and presented to a wide variety of audiences including the Royal Society, the ICBD and WHO International Symposium on Prevention & Epidemiology of Congenital Malformations and Maxillofacial Surgical Unit at Great Ormond Street Hospital.

**Andrew T. McAfee, MD, MS**  
**Executive Director, Epidemiology, i3 Drug Safety**

Andrew T. McAfee joined the epidemiology group in 2004. After completing a residency in emergency medicine at Boston Medical Center in 1994, he served as associate research director and director of information systems for the Department of Emergency Medicine at Brigham and Women's Hospital in Boston and as an instructor at Harvard Medical School. His research has focused on the delivery and impact of emergency care with an emphasis on risk stratification and diagnostics. Since joining the epidemiology group at i3 Drug Safety his research has focused on pharmacoepidemiology and natural history of disease epidemiology, along with acting as a medical consultant on pharmacosafety projects. He serves as statistical consultant to the peer-reviewed journal Academic Emergency Medicine, and as an ad-hoc reviewer for the Journal of Emergency Medicine, Pharmacoepidemiology and Drug Safety, and JAMA. He earned a Bachelor of Science in mathematics and physics from Yale University in 1983, a Doctorate of Medicine from Boston University School of Medicine in 1990, and a Master of Science in Epidemiology from the Harvard School of Public Health in 2002.

**John D. Seeger, PharmD, DrPH**  
**Senior Scientist, i3 Drug Safety**

John D. Seeger is a pharmacoepidemiologist who has been working with i3 Drug Safety since 2001 and has conducted numerous studies that have addressed regulatory drug safety issues involving a wide array of drugs and disease conditions, largely within an insurance claims environment. Dr. Seeger received a PharmD from the University of Arizona, a MPH from the University of Michigan, and a DrPH from the Harvard School of Public Health. Originally trained as a clinical pharmacist, Dr. Seeger spent three years on the faculty of the University of Illinois at Chicago where he also completed a residency in pharmacy practice. Dr. Seeger's research interest is in predictors of drug therapy and research methods that incorporate these predictors. He has worked extensively with propensity scores and related methods that seek to mitigate confounding by modeling drug therapy as a function of covariates, and he teaches a course on propensity scores at Harvard School of Public Health. He has authored or co-authored more than 30 articles in the peer-reviewed medical literature.